Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strata Skin SciencesSSKN Debt-to-EBITDA is 2.79 as of Dec. 2025, which is 32% below its 10-year median of 4.13. The stock has 4 warning signs investors should review. Among 478 Medical Devices & Instruments companies, Strata Skin Sciences ranks worse than 209204.81% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Strata Skin Sciences's Debt-to-EBITDA or its related term are showing as below:
SSKN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -725.47 Med: 4.13 Max: 91.91
Current: -346.13
During the past 13 years, the highest Debt-to-EBITDA Ratio of Strata Skin Sciences was 91.91. The lowest was -725.47. And the median was 4.13.
SSKN's Debt-to-EBITDA is ranked worse than 100% of 478
companies
in the Medical Devices & Instruments industry
Industry Median: 1.65
vs SSKN: -346.13
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Strata Skin Sciences Debt-to-EBITDA Related Terms
Strata Skin Sciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Strata Skin Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Skin Sciences Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Strata Skin Sciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
Strata Skin Sciences (SSKN) has a Debt-to-EBITDA of 2.79 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Strata Skin Sciences. This is 32% below median its historical median of 4.13. According to the industry distribution chart, Strata Skin Sciences ranks #999999 out of 478 companies in the Medical Devices & Instruments industry.
Is Strata Skin Sciences' Debt-to-EBITDA too high?
Strata Skin Sciences' current Debt-to-EBITDA of 2.79 is 32% below median its 10-year median of 4.13. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.65. Strata Skin Sciences' value of 2.79 is 69.1% above this industry median. Based on the distribution chart, Strata Skin Sciences ranks #999999 out of 478 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Strata Skin Sciences' Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Strata Skin Sciences ranks #999999 out of 478 companies for Debt-to-EBITDA. This places Strata Skin Sciences in the lower half of its industry. The industry median Debt-to-EBITDA is 1.65. Strata Skin Sciences' value of 2.79 is 69.1% above this benchmark. While the company's 10-year median is 4.13 vs. the industry median of 1.65, Strata Skin Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.65, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strata Skin Sciences's current Debt-to-EBITDA of 2.79 is 69.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Strata Skin Sciences. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Skin Sciences's current Debt-to-EBITDA is 2.79, which is 32% below median its own 10-year median of 4.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Based on GuruFocus' analysis, Strata Skin Sciences (SSKN) is currently considered Possible Value Trap. The stock's GF Value™ is $2.00, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current Debt-to-EBITDA is 2.79, which is 32% below median its 10-year median of 4.13 and 69.1% above the Medical Devices & Instruments industry median of 1.65. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Strata Skin Sciences (SSKN), the current Debt-to-EBITDA is 2.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SSKN has been successfully added to your 
